Pharmaceutical

NRx Pharmaceuticals Expands Access to NRX-100 for Suicidal Depression
Clinical & Pharma NRx Pharmaceuticals Expands Access to NRX-100 for Suicidal Depression

In a landscape where mental health crises continue to escalate, a staggering statistic from the Centers for Disease Control and Prevention reveals that around 13 million adults in the U.S. contemplate suicide each year, with a tragic loss occurring every 11 minutes, highlighting a critical gap in

North Dakota Law Sparks Legal Battle Over Drug Discounts
Clinical & Pharma North Dakota Law Sparks Legal Battle Over Drug Discounts

In a striking development that underscores the ongoing tension between state healthcare initiatives and pharmaceutical giants, North Dakota finds itself at the center of a heated legal confrontation. A recently enacted state law, known as House Bill 1473, seeks to safeguard hospitals’ access to

Will US-EU Tariffs Raise Costs for Drugs Like Ozempic?
Clinical & Pharma Will US-EU Tariffs Raise Costs for Drugs Like Ozempic?

The landscape of American healthcare is facing a significant shakeup with the recent announcement of a US-EU trade agreement that introduces a 15 percent tariff on branded pharmaceuticals imported from Europe, raising alarms for millions of patients who depend on critical medications. This policy,

What Does West Pharma’s $494M ESOP Mean for Investors?
Clinical & Pharma What Does West Pharma’s $494M ESOP Mean for Investors?

West Pharmaceutical Services (WST), a key player in the medical packaging and delivery systems arena, has recently captured attention with a $494 million shelf registration linked to an Employee Stock Ownership Plan (ESOP). This filing, which involves the potential issuance of 2 million

Debunking False Claims on Groundbreaking RSV Therapies
Clinical & Pharma Debunking False Claims on Groundbreaking RSV Therapies

In a world where medical advancements are often met with both hope and skepticism, the battle against Respiratory Syncytial Virus (RSV) stands as a testament to human ingenuity, yet it is not without its controversies. RSV, a pervasive respiratory illness, has long been a leading cause of

J&J Invests $2B in US Drug Manufacturing with Fujifilm Hub
Clinical & Pharma J&J Invests $2B in US Drug Manufacturing with Fujifilm Hub

In a groundbreaking move that underscores the pharmaceutical industry's shift toward domestic production, Johnson & Johnson has committed a staggering $2 billion to a ten-year partnership with Fujifilm Biotechnologies at a new manufacturing hub in Holly Springs, North Carolina. This investment is

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later